A Year in Review and a Look to the Future: BTKi in CLL and MCL

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: 

SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL ZUMA-2: Brexucabtagene Autoleucel in R/R MCL BRUIN: Pirtobrutinib for Previously Treated MCL GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL BRUIN: Pirtobrutinib for Previously Treated CLL

Presenters: 

Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Link to full program: 
https://bit.ly/3MNaUri